Back to Search
VIRGINIA GATES, PHARMD
PHARMD
Pharmacist
NPI: 1588188627Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
E-15025(MS)
Research & Publications (20)
Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization.
PMID 19357924·Ann Surg Oncol·2009
8-other
Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors.
PMID 19157721·Int J Radiat Oncol Biol Phys·2009
4-observational
Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres.
PMID 19133645·Hepatology·2009
8-other
MR tracking of iron-labeled glass radioembolization microspheres during transcatheter delivery to rabbit VX2 liver tumors: feasibility study.
PMID 18840788·Radiology·2008
7-preclinical
Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution.
PMID 18838878·Am J Clin Oncol·2008
3-trial
Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review.
PMID 18350597·World J Gastroenterol·2008
6-review
Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival.
PMID 18349311·Radiology·2008
8-other
Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.
PMID 18027884·Hepatology·2008
3-trial
Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma.
PMID 18003987·J Vasc Interv Radiol·2007
3-trial
90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival.
PMID 17494843·J Vasc Interv Radiol·2007
3-trial
Radioembolization with Yttrium-90 microspheres: review of an emerging treatment for liver tumors.
PMID 17280504·Future Oncol·2007
6-review
Regional yttrium-90 microsphere treatment of surgically unresectable and chemotherapy-refractory metastatic liver carcinoma.
PMID 16999596·Cancer Biother Radiopharm·2006
3-trial
90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging.
PMID 16371530·J Vasc Interv Radiol·2005
3-trial
Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival.
PMID 16371529·J Vasc Interv Radiol·2005
3-trial
Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging.
PMID 16105922·J Vasc Interv Radiol·2005
8-other
The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma.
PMID 16105920·J Vasc Interv Radiol·2005
8-other
Angiographic considerations in patients undergoing liver-directed therapy.
PMID 16002500·J Vasc Interv Radiol·2005
6-review
Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET.
PMID 15534060·J Nucl Med·2004
3-trial
Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.
PMID 12029557·Eur J Nucl Med Mol Imaging·2002
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3189 HIGHWAY 80 E
PEARL, MS 39208 - Phone
- (601) 664-0641
Quick Facts
- NPI
- 1588188627
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile